These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 28056549)
1. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells. Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549 [TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine delivered by high proportion PEG of long- circulating liposomes inhibits RPMI8226 multiple myeloma cells in vitro and in vivo. Li M; Fei X; Shi F; Dou J; Wu S; Wu D; Zhang Y; Pan M; Luo S; Gu N Am J Transl Res; 2016; 8(3):1355-68. PubMed ID: 27186264 [TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice. Yang C; Wang J; Chen D; Chen J; Xiong F; Zhang H; Zhang Y; Gu N; Dou J Int J Nanomedicine; 2013; 8():1439-49. PubMed ID: 23610522 [TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Lou YJ; Qian WB; Jin J Leuk Lymphoma; 2007 Jul; 48(7):1400-6. PubMed ID: 17613769 [TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Meng H; Yang C; Jin J; Zhou Y; Qian W Leuk Lymphoma; 2008 Oct; 49(10):1954-62. PubMed ID: 18949618 [TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts. Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768 [TBL] [Abstract][Full Text] [Related]
7. Enhancing the anti-multiple myeloma efficiency in a cancer stem cell xenograft model by conjugating the ABCG2 antibody with microbubbles for a targeted delivery of ultrasound mediated epirubicin. Shi F; Li M; Wu S; Yang F; Di W; Pan M; Zhao F; Luo S; Gu N; Dou J Biochem Pharmacol; 2017 May; 132():18-28. PubMed ID: 28232025 [TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft. Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644 [TBL] [Abstract][Full Text] [Related]
9. [Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1]. Shen JP; Yang H; Ni WM; Qian WB Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):485-90. PubMed ID: 23086639 [TBL] [Abstract][Full Text] [Related]
10. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research]. Zhou XJ; Zhou YH; Chen XH; Qian WB Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):834-9. PubMed ID: 23980369 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of epirubicin-loaded lipid microbubbles with conjugated anti-ABCG2 antibody combined with therapeutic ultrasound on multiple myeloma cancer stem cells. Shi F; Yang F; He X; Zhang Y; Wu S; Li M; Zhang Y; Di W; Dou J; Gu N J Drug Target; 2016; 24(1):34-46. PubMed ID: 26204324 [TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy. Zhang Y; Huang N; Xu J; Zheng W; Cui X Drug Des Devel Ther; 2020; 14():4749-4763. PubMed ID: 33177810 [TBL] [Abstract][Full Text] [Related]
13. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Kuroda J; Kamitsuji Y; Kimura S; Ashihara E; Kawata E; Nakagawa Y; Takeuichi M; Murotani Y; Yokota A; Tanaka R; Andreeff M; Taniwaki M; Maekawa T Int J Hematol; 2008 Jun; 87(5):507-515. PubMed ID: 18415656 [TBL] [Abstract][Full Text] [Related]
14. Gamma-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model. Yang C; He X; Song L; Zhan X; Zhang Y; Dou J; Gu N J Biomed Nanotechnol; 2014 Feb; 10(2):336-44. PubMed ID: 24738341 [TBL] [Abstract][Full Text] [Related]
15. Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes. Liu D; Xing J; Xiong F; Yang F; Gu N Drug Dev Ind Pharm; 2017 Apr; 43(4):652-660. PubMed ID: 28005445 [TBL] [Abstract][Full Text] [Related]
16. Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model. Yang C; Xiong F; Dou J; Xue J; Zhan X; Shi F; Li M; Wu S; Luo S; Zhang T; Zhang Y; Ming J; Gu N Oncotarget; 2015 Sep; 6(29):27714-24. PubMed ID: 26314844 [TBL] [Abstract][Full Text] [Related]
17. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. Tan M; Zhang Q; Yuan X; Chen Y; Wu Y J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525 [TBL] [Abstract][Full Text] [Related]
18. Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles. Shi F; Li M; Wang J; Wu D; Pan M; Guo M; Dou J Stem Cell Res Ther; 2018 May; 9(1):144. PubMed ID: 29784015 [TBL] [Abstract][Full Text] [Related]
19. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Yang C; Xiong F; Wang J; Dou J; Chen J; Chen D; Zhang Y; Luo S; Gu N Nanomedicine (Lond); 2014 Jan; 9(1):45-60. PubMed ID: 23534833 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]